KOS 3334 Page 10f3

ELASTO-GEL MANUKA HONEY WOUND DRESSING

JUL 3 0 2009

1. Sponsor:

Southwest Technologies, Inc.

1746 Levee Road:

N. Kansas City, MO 64116

Contact Person:

Edward T. Stout, CEO

Southwest Technologies, Inc.

1746 Levee Rd

N. Kansas City, MO 64116

Telephone:

(816) 221-2442

Fax:

(816) 221-3995

email:

swtech@birch.net

2. Device Name and Classification

Proprietary Name Elasto-Gel Manuka Honey Wound Dressing

Common Name:

Wound Dressing

Classification Name

Dressing (Product code KMF? FRO???) Classification: Tomy knowledge, FDA has not classified this device.

3. Substantial Equivalence Claim- Predicate Devices

Legally marketed devices

Elasto-Gel Occlusive Dressing by Southwest Technologies (K872165)

Derma Sciences API MEDTM Active Manuka Honey Absorbent Dressing by Derma Sciences Canada, Inc (K053095) Product Code FRO

Derma Sciences Medihoney Primary Dressings with Active Manuka Honey by Derma Sciences (K072956)

4. Device Description

Elasto-Gel Manuka dressings are supplied as a gel(amorphous) or gel sheet. Elasto-Gel Manuka Honey sheet dressing is a sterile primary single use dressing comprised of an insoluble polyacrylamide polymer matrix in the form of a continuous sheet with plasticizer of glycerine, honey, and water. The dressings will be supplied in many sizes, for example: 2x3", 4x4, 6x8, and possibly other additional sizes and shapes. The amorphous gel is a mixture of a super absorbent crosslinked sodium polyacrylic acid, glycerine, honey and water. The crosslinked polyacrylamide polymer is insoluble in the wound fluid but has a relatively high capacity for absorption of the wound fluid, while releasing the glycerine, honey, and water into the wound fluid to establish a chemical equilibrium. The Elasto-Gel Manuka Honey amorphous gel dressing, is formulated to produce a high viscosity fluid mixture suitable for filling wound cavities. The gel sheet is a moderately adhesive soft gel sheet that will protect the wound from shear, friction and pressure, suitable as a protective padding and cushioning device as well as functioning as a dressing.


The products will not dry out or become stuck to the wound. In most cases soon after application to the wound the pain level will be diminished. The products will help provide a moist healing environment and will absorb excess wound exudate.



5. Intended Use

These products are suitable for:

- full and partial thickness wounds,
- pressure ulcers (stages I-IV)
- venous stasis ulcers
- diabetic ulcers
- partial thickness burns
- acute wounds
- abrasions
- traumatic wounds healing by secondary intention





southwest technologies inc. "Treating the world well"

6. Technological Characteristics and Substantial Equivalence **Comparison to Predicate Devices**

Device Name	Elasto-Gel™	Medihoney Primary	APIMED™	Elasto-Gel™	3 77
	Manuka Honey	Dressing 🦯	ACTIVEMANUKA	Occlusive wound	
	Wound Dressing		HONEY ABSORBENT	Dressing	Alak in the second second
Manufacture	0 4	A 100 miles	DRESSING /	\$最后,17.美格·朱子。	
Manufacturer	Southwest Techologies Inc	Derma Sciences	Derma Sciences	Southwest Technologies; Inc	
Indications	Prolonged use in	Used to manage/	Used in the	Used in the	
For use	Full and partial thick-	A. 海川勝ち ご・ご	Management.	Management of	A STATE OF THE STA
1 01 430	ness chronic and	moderate amounts	Of chronic and acute	partial and full	
	acute wounds.	∠ of, exudate.	wounds:	thickness and partial	radi Trisi
				chronic and Acute	
		4.0		wounds.	
	1				
Material	Polyacrylamide+glyc rine+Water + Manuk	e Manuka Honey	Manuka Honey∔ ∖ Alginate	Polyacrylamide+ glycerine + Water	
	Honey or	a i Aginate	Alginate	glyceime + vvalei	
	PolyAcrylate +				
	Water + Manuka				
	honey +glycerine				
· · · · · · · · · · · · · · · · · · ·			4:57		A Marian
Honey	New Zealand	'	No. of the second	· NA	
Source					V. I
Properties of		-		TO THE STATE OF TH	\ .
Sheet Absorbent Soft				(Artist And	\\
Sheet	Yes	Yes	Yes	Yes	1
				7.37	,
Disolves or			. ,		
"melts" in wound fluid	No No	Yes	Yes		
noro	140	1 CS.	Tes	No	
Bio-	V A	1. 1	W.A.	18.1	
Compatibility	Yes	Yes	Yes	Yes	
Sterile	Yes 🦞	7 A Yes	Yes	Yes	7. 精硬化生活物的方式
	, , , , , , , , , , , , , , , , , , ,	And Andrews		V. 3-7-15	Look

7. Performance Testing

The biocompatibility testing and case studies demonstrates that these dressings are safe for their intended use. Cytotoxicity, sensitization, acute systemic injection, intracutaneous, and irritation testing was performed





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Southwest Technologies, Inc. % Mr. Edward I. Stout 1746 Levee Road N. Kansas City, Missouri 64116 JUL 3 0 2009

Re: K083334

Trade/Device Name: Elasto-Gel Manuka Honey Wound Dressing

Regulatory Class: Unclassified

Product Code: FRO Dated: June 22, 2009 Received: June 23, 2009

Dear Mr. Stout:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Director

Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use

510 (k) Number (If Known): K083334

Device Name: Elasto-Gel Manuka Honey Wound Dressing

Indications For Use:

Elasto-gel Manuka Honey wound Dressings are indicated for use in management of wounds. Full and partial thickness wounds, pressure ulcers, (stages 1 –IV) venous stasis ulcers, diabetic ulcers, abrasions, surface wounds, traumatic wounds (healing by secondary intention), donor site wounds, and surgical wounds

Prescription Use X AND/OR (Part 21CFR 801 Subpart D)

Over-the-Counter (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number <u>KO83334</u>

Page 1 of 1